Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06423264 Phase 1 MAD Study
NCT02778477Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06423264 in acne vulgaris (18 cohorts), sponsored by Pfizer. Primary endpoints: Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) or other safety concerns, Number of Participants with Draize-like scoring and clinical observation and 3 more. Started May 2016; status: terminated.
02
Drugs
PF-06423264
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02778477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778477.